These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

768 related articles for article (PubMed ID: 27320035)

  • 41. Cumulative live birth rates between GnRH-agonist long and GnRH-antagonist protocol in one ART cycle when all embryos transferred: real-word data of 18,853 women from China.
    Yang J; Zhang X; Ding X; Wang Y; Huang G; Ye H
    Reprod Biol Endocrinol; 2021 Aug; 19(1):124. PubMed ID: 34384445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of elevated peak serum progesterone levels.
    Orvieto R; Nahum R; Meltzer S; Liberty G; Anteby EY; Zohav E
    Gynecol Endocrinol; 2013 Sep; 29(9):843-5. PubMed ID: 23802563
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is the flexible GnRH antagonist protocol better suited for fresh eSET cycles?
    Dahdouh EM; Gomes FL; Granger L; Carranza-Mamane B; Faruqi F; Kattygnarath TV; St-Michel P
    J Obstet Gynaecol Can; 2014 Oct; 36(10):885-891. PubMed ID: 25375301
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

  • 45. How compliant are in vitro fertilization member clinics in following embryo transfer guidelines? An analysis of 59,689 fresh first in vitro fertilization autologous cycles from 2011 to 2012.
    Keyhan S; Acharya KS; Acharya CR; Yeh JS; Provost MP; Goldfarb JM; Muasher SJ
    Fertil Steril; 2016 Sep; 106(3):645-652.e1. PubMed ID: 27268276
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased odds of live birth in fresh in vitro fertilization cycles with shorter ovarian stimulation.
    Pereira N; Friedman C; Hutchinson AP; Lekovich JP; Elias RT; Rosenwaks Z
    Fertil Steril; 2017 Jan; 107(1):104-109.e2. PubMed ID: 27793370
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles.
    Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY
    Fertil Steril; 2008 Apr; 89(4):860-7. PubMed ID: 18249372
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Longer ovarian stimulation reduces embryo number and clinical pregnancy rate in long GnRH agonist cycles.
    Dunne C; Lawrence C; Albert A; Havelock JC
    Minerva Ginecol; 2017 Apr; 69(2):135-140. PubMed ID: 27270672
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
    Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial.
    Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L
    Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization.
    Berin I; Stein DE; Keltz MD
    Fertil Steril; 2010 Feb; 93(2):360-3. PubMed ID: 19131055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in vitro fertilization/embryo transfer programs.
    Orvieto R; Kruchkovich J; Rabinson J; Zohav E; Anteby EY; Meltcer S
    Fertil Steril; 2008 Jul; 90(1):228-30. PubMed ID: 17681292
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparison of the effects of three luteal phase support protocols with estrogen on in vitro fertilization-embryo transfer outcomes in patients on a GnRH antagonist protocol.
    Scheffer JB; Scheffer BB; Carvalho RF; Aguiar AP; Lozano DHM; Labrosse J; Grynberg M
    JBRA Assist Reprod; 2019 Aug; 23(3):239-245. PubMed ID: 30875186
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates.
    Griffin D; Feinn R; Engmann L; Nulsen J; Budinetz T; Benadiva C
    Fertil Steril; 2014 Aug; 102(2):405-9. PubMed ID: 24842671
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation between Ovarian Reserve and Incidence of Ectopic Pregnancy after
    Kim SW; Kim YJ; Shin JH; Kim H; Ku SY; Suh CS; Kim SH; Choi YM
    Yonsei Med J; 2019 Mar; 60(3):285-290. PubMed ID: 30799591
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Delayed Start Versus Conventional GnRH Antagonist Protocol in Poor Responders Pretreated With Estradiol in Luteal Phase: A Randomized Controlled Trial.
    Maged AM; Nada AM; Abohamila F; Hashem AT; Mostafa WA; Elzayat AR
    Reprod Sci; 2015 Dec; 22(12):1627-31. PubMed ID: 26045549
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the GnRH agonist and antagonist protocol on the same patients in assisted reproduction during controlled ovarian stimulation cycles.
    Lai Q; Zhang H; Zhu G; Li Y; Jin L; He L; Zhang Z; Yang P; Yu Q; Zhang S; Xu JF; Wang CY
    Int J Clin Exp Pathol; 2013; 6(9):1903-10. PubMed ID: 24040457
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive factors for oocyte retrieval failure in controlled ovarian hyperstimulation protocols: a retrospective observational cohort study.
    Hasegawa A; Takahashi T; Igarashi H; Amita M; Matsukawa J; Nagase S
    Reprod Biol Endocrinol; 2015 Jun; 13():53. PubMed ID: 26033112
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles.
    Meyer L; Murphy LA; Gumer A; Reichman DE; Rosenwaks Z; Cholst IN
    Fertil Steril; 2015 Sep; 104(3):637-42. PubMed ID: 26149355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.